Committed to trials of Low Dose Naltrexone as a treatment for autoimmune diseases

Text Resize

-A +A
The LDN 2016 AIIC Conference - Orlando
February 19th, 20th & 21st - Double Tree Orlando Airport
Low Dose Naltrexone (LDN) is a drug that may help regulate a dysfunctional immune system in autoimmune diseases.

About LDN Research Trust

The primary aim of the Trust is to initiate Clinical Trials of Low Dose Naltrexone, help and support those who have a condition where LDN could be of benefit obtain a prescription around the world.

Download the LDN Information Pack which can be printed, to show your doctor.

Whilst working to raise funds for trials, we have helped over 18,000 people  to obtain LDN from a General Practitioner or Neurologist, either through the National Health Service or by private prescription.  We have also been able to help people, not just in the UK but in countries throughout Europe, as well as USA, Canada, West Indies, Australia, New Zealand, and others. 

Find out more

“The Game Changer”

The use of Low Dose Naltrexone (LDN) in cancer treatment has been examined for some time and now we are on the verge of a major breakthrough in its use to treat and kill cancer cells, this documentary will investigate a major break through in cancer treatment using Low Dose Naltrexone.

To find out more click here.


The LDN Book

The LDN Book will be launched at the LDN 2016 Conference.

Find out more

The LDN 2016 AIIC Conference in Orlando is now on sale.

February 19,20,21 DoubleTree Airport Hotel

To sign up and secure your tickets please click here.

This conference will review, compare and contrast the most recent data and treatments for a variety of Auto-Immune and Immuno-modulated Conditions.

Should you still wish to view the presenations made at the 2014 conference in Las Vegas please click here

Featured Video

This documentary was produced for the LDN Research Trust after it was funded successfully on Start Some Good.

It aims to explore some of the uses of LDN, encourage wider knowledge of LDN and educate watchers further with a view to encouraging clinical trials.